Cargando…
TGF-β2 Reduces the Cell-Mediated Immunogenicity of Equine MHC-Mismatched Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Immunomodulatory Properties
Allogeneic mesenchymal stem cells (MSCs) are a promising cell therapy for treating numerous diseases, but major histocompatibility complex (MHC)-mismatched MSCs can be rejected by the recipient’s immune system. Pre-treating MSCs with transforming growth factor-β2 (TGF-β2) to downregulate surface exp...
Autores principales: | Berglund, Alix K., Long, Julie M., Robertson, James B., Schnabel, Lauren V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889809/ https://www.ncbi.nlm.nih.gov/pubmed/33614658 http://dx.doi.org/10.3389/fcell.2021.628382 |
Ejemplares similares
-
TGF-β2 enhances expression of equine bone marrow-derived mesenchymal stem cell paracrine factors with known associations to tendon healing
por: Koch, Drew W., et al.
Publicado: (2022) -
Transforming Growth Factor-β2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers
por: Berglund, Alix K., et al.
Publicado: (2017) -
Effect of bone marrow-derived mesenchymal stem cells and stem cell supernatant on equine corneal wound healing in vitro
por: Sherman, Amanda B., et al.
Publicado: (2017) -
Allogeneic major histocompatibility complex‐mismatched equine bone marrow‐derived mesenchymal stem cells are targeted for death by cytotoxic anti‐major histocompatibility complex antibodies
por: Berglund, A.K., et al.
Publicado: (2016) -
Immunomodulatory Properties of Mesenchymal Stromal Cells: An Update
por: Müller, Luise, et al.
Publicado: (2021)